Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Patisiran: Post-Orthotopic Liver Transplant
Standard response letter on patisiran and the open-label phase 3 study evaluating the efficacy, safety and PK of patisiran in patients with hATTR who had polyneuropathy progression post-OLT. Additional summaries of case reports are also included.
Standard response letter on patisiran and the open-label phase 3 study evaluating the efficacy, safety and PK of patisiran in patients with hATTR who had polyneuropathy progression post-OLT. Additional summaries of case reports are also included.
Lumasiran: ILLUMINATE-C Study Overview
Standard response letter on lumasiran phase 3 clinical study ILLUMINATE-C, a study evaluated the efficacy and safety of lumasiran in infants to adult patients with PH1 and advanced kidney disease.
Standard response letter on lumasiran phase 3 clinical study ILLUMINATE-C, a study evaluated the efficacy and safety of lumasiran in infants to adult patients with PH1 and advanced kidney disease.
Vutrisiran: Post-Hoc Analysis of HELIOS-A Results by Baseline NIS Quartile
Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.
Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.
Vutrisiran: Technetium Scintigraphy
Standard response letter on vutrisiran and technetium scintigraphy data assessed in a subset of patients from the HELIOS-A study.
Standard response letter on vutrisiran and technetium scintigraphy data assessed in a subset of patients from the HELIOS-A study.
Vutrisiran: Injection Site Reactions
Standard response letter on vutrisiran and injection site reactions.
Standard response letter on vutrisiran and injection site reactions.
Patisiran: Use in Patients with Wild-Type ATTR
Standard response letter on patisiran and its use in patients with wild-type transthyretin amyloidosis in the APOLLO and APOLLO-B studies.
Standard response letter on patisiran and its use in patients with wild-type transthyretin amyloidosis in the APOLLO and APOLLO-B studies.
